Why the study?
Does a tailored treatment approach based on disease phase improve outcomes in patients with ventricular tachycardia and cardiac sarcoidosis?
Does a tailored treatment approach based on disease phase improve outcomes in patients with ventricular tachycardia and cardiac sarcoidosis?
Tailoring therapy for ventricular tachycardia in cardiac sarcoidosis based on the presence of active inflammation versus scar tissue yields good clinical outcomes and avoids unnecessary immunosuppression.
No takes yet. Share an insight, caveat, or question.
Supports phase-guided VT management in CS; leaves open need for prospective validation.
Yalagudri et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: